A Phase 2 interventional study of L-Arginine Powder and Placebo in Heart Failure, sponsored by German University in Cairo. Not yet recruiting at 1 site in Egypt. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by German University in Cairo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Heart Failure with a site in Egypt — 16 open to participants now, 21 under way, 2 of them phase 3. Heart Failure · Egypt.
Among the 63 studies in Heart Failure with a site in Egypt, this one is the 3rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 2, reaches primary completion later than 17 of the 20 other live ones, and was the 52nd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 63 studies in Heart Failure with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 45–65
Tanta University · Sites in Egypt
Ages 18+
Future University in Egypt · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 6 · Phase 4 12
First in 2014; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 68 across the 46 interventional studies, 140 across the 17 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 63 have an industry lead sponsor. The 10 most frequent:
German University in Cairo is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
German University in Cairo has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841665Alexandria UniversityAI-Based Personalized Self-Management for Patients With Heart Failure | 2026-12 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT07930390Alexandria UniversityHandheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease | 2027-02-03 |
| NCT07394270German University in CairoEffect of Add-on L-Arginine Therapy on Heart Failure Patients | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Heart Failure with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will be administered 6 gm L-arginine per day
Drug: L-Arginine Powder
Patients in this arm will take 6 gm placebo per day
Drug: Placebo
L-arginine 3 gm sachets are used twice daily
2 sachets of placebo are administered per day
Change of Global longitudinal strain value (GLS) of HF patients from the baseline
Time frame: 6 weeks
Change of heart failure symptoms as determined by NYHA classification from baseline
Time frame: 6 weeks
Change of the functional abilities (ECG) of the patients as determined by the exercise test from baseline
Time frame: 6 weeks
Changes in biomarkers of heart failure as determined by the difference in NT-proBNP levels from baseline
Time frame: 6 weeks
Change in quality of life between 2 groups as determined by Minnesota Living with Heart Failure questionnaire
Time frame: 6 weeks
Safety profile of the L-Arginine as determined by the change in the mean arterial pressure (MAP) between the 2 groups
Time frame: 6 weeks
Change in biomarkers of endothelial dysfunction as determined by the difference in levels of endothelin-1
Time frame: 6 weeks
Change in biomarkers of endothelial dysfunction as determined by the difference in levels of Asymmetric dimethylarginine (ADMA)
Time frame: 6 weeks
Safety profile of the L-Arginine as determined by the change in the heart rate (HR) between the 2 groups
Time frame: 6 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Mar 2027, 13 months later.
Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 13 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine
German University in Cairo